165 related articles for article (PubMed ID: 31261551)
1. Safety and efficacy of pulsed low-dose rate radiotherapy for local recurrent esophageal squamous cell carcinoma after radiotherapy: Study protocol for a prospective multi-center phase II trial.
Li J; Zhao Z; Du G; Dai T; Zhen X; Cai H; Liao D; Xiang M; Wen Y; Geng L; Yang X; Feng G; Zhang Y; Bai J; Liu L; Du X
Medicine (Baltimore); 2019 Jun; 98(26):e16176. PubMed ID: 31261551
[TBL] [Abstract][Full Text] [Related]
2. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol.
Gao LR; Wang X; Han W; Deng W; Li C; Wang X; Zhao Y; Ni W; Chang X; Zhou Z; Deng L; Wang W; Liu W; Liang J; Zhang T; Bi N; Wang J; Zhai Y; Feng Q; Lv J; Li L; Xiao Z
BMC Cancer; 2020 Sep; 20(1):901. PubMed ID: 32962674
[TBL] [Abstract][Full Text] [Related]
3. A re-irradiation dose of 55-60 Gy improves the survival rate of patients with local recurrent esophageal squamous cell carcinoma after radiotherapy.
Wu X; Hu X; Chen J; He L
Radiat Oncol; 2021 Jun; 16(1):100. PubMed ID: 34103059
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the optimal re-irradiation dose for locally recurrent esophageal squamous cell carcinoma after definitive radiotherapy.
Xu X; Wang Z; Jiang S; Shang Y; Wu Y
Radiat Oncol; 2019 Nov; 14(1):191. PubMed ID: 31684983
[TBL] [Abstract][Full Text] [Related]
5. High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial.
Lertbutsayanukul C; Kitpanit S; Kannarunimit D; Chakkabat C; Oonsiri S; Thephamongkhol K; Puataweepong P; Katanyoo K; Sukhaboon J; Tovanabut C; Chongsathientham S; Treeratsapanich P; Soonthornrak J; Prayongrat A
Trials; 2022 Oct; 23(1):897. PubMed ID: 36273186
[TBL] [Abstract][Full Text] [Related]
6. Re-irradiation for local primary-recurrence esophageal squamous cell carcinoma treated with IMRT/VMAT.
Xiang G; Xu C; Chai G; Lyu B; Li Z; Wang B; Shi M; Zhao L
Radiat Oncol; 2023 Jul; 18(1):114. PubMed ID: 37430276
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of re-irradiation for locoregional esophageal squamous cell carcinoma recurrence after radiotherapy: a systematic review and meta-analysis.
Lan K; Chen J
Radiat Oncol; 2022 Mar; 17(1):61. PubMed ID: 35346285
[TBL] [Abstract][Full Text] [Related]
8. Caution against simultaneous integrated boost radiotherapy for upper thoracic esophageal squamous cell carcinoma: results from a single-arm phase II trial.
Zhou Y; Chu L; Lu S; Chu X; Ni J; Li Y; Guo T; Yang X; Zhu Z
Esophagus; 2023 Oct; 20(4):713-721. PubMed ID: 37149827
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic analysis of definitive radiotherapy for early esophageal carcinoma(T1-2N0M0): a multi-center retrospective study of Jing-Jin-ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group].
Lu N; Wang X; Li C; Wang L; Chen JQ; Zhang WC; Wang XM; Ge XL; Shen WB; Hu MM; Yuan QQ; Xu YG; Hao CL; Zhou ZG; Qie S; Xiao ZF; Zhu SC; Han C; Qiao XY; Pang QS; Wang P; Zhao YD; Sun XC; Zhang KX; Li L; Li GF; Liu ML; Wang YD
Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):139-144. PubMed ID: 32135649
[No Abstract] [Full Text] [Related]
10. Efficacy and toxicity of re-irradiation for esophageal cancer patients with locoregional recurrence: a retrospective analysis.
Zhao K; Si Y; Sun L; Meng X; Yu J
Radiat Oncol; 2020 Oct; 15(1):243. PubMed ID: 33087143
[TBL] [Abstract][Full Text] [Related]
11. High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma.
Lertbutsayanukul C; Tharavej C; Klaikeaw N; Prayongrat A; Lowanitchai C; Sriuranpong V
Thorac Cancer; 2017 May; 8(3):219-228. PubMed ID: 28322515
[TBL] [Abstract][Full Text] [Related]
12. Involved-Field Irradiation in Definitive Chemoradiotherapy for Locoregional Esophageal Squamous Cell Carcinoma: Results From the ESO-Shanghai 1 Trial.
Zhu H; Rivin Del Campo E; Ye J; Simone CB; Zhu Z; Zhao W; Amini A; Zhou J; Wu C; Tang H; Fan M; Li L; Lin Q; Xia Y; Li Y; Li J; Mo M; Jia H; Lu S; Wang J; Nie Y; Chen J; Wu S; Hamaji M; Haque W; Jeong BK; Shridhar R; Zhang Z; Chen Y; Zhao K
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1396-1406. PubMed ID: 33677048
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy analysis of the radiotherapy and chemotherapy in patients with stage Ⅳ esophageal squamous carcinoma: a multicenter retrospective study of Jing-Jin-Ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group (3JECROG R-01F)].
Hu MM; Yuan QQ; Zhang XS; Yang S; Wang X; Wang L; Chen JQ; Zhang WC; Wang XM; Ge XL; Shen WB; Xu YG; Hao CL; Zhou ZG; Qie S; Lu N; Pang QS; Zhao YD; Sun XC; Li GF; Li L; Qiao XY; Liu ML; Wang YD; Li C; Zhu SC; Han C; Zhang KX; Xiao ZF
Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):676-681. PubMed ID: 32867461
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of PLDR-IMRT for the re-irradiation of recurrent NPC: A prospective, single-arm, multicenter trial.
Huang R; Li Z; Yang F; Zhang Y; Jiang Y; Li C; Gao H; Li G; Liu Y; Guo W; Yang D; Zhang S; Li J; Wen H; Lang J; Zhang P
Cancer Sci; 2023 Jun; 114(6):2534-2543. PubMed ID: 36788727
[TBL] [Abstract][Full Text] [Related]
15. Intensity-modulated radiotherapy for cervical esophageal squamous cell carcinoma without hypopharyngeal invasion: dose distribution and clinical outcome.
Ishida Y; Sakanaka K; Fujii K; Itasaka S; Mizowaki T
J Radiat Res; 2019 Jul; 60(4):517-526. PubMed ID: 31083715
[TBL] [Abstract][Full Text] [Related]
16. Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas.
Cheng N; Liu Y; Zhao G; Xu Y; Zhang T; Chen Y; Yan G; Hu Y; Yao S; Wang Z; Wang C; Chen Z; Hu Z; Liu D; Chen T
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):340-348. PubMed ID: 31655197
[TBL] [Abstract][Full Text] [Related]
17. Radiation Dose-escalated Chemoradiotherapy Using Simultaneous Integrated Boost Intensity-Modulated Radiotherapy for Locally Advanced Unresectable Thoracic Oesophageal Squamous Cell Carcinoma: A Single-institution Phase I Study.
Sakanaka K; Ishida Y; Fujii K; Ishihara Y; Nakamura M; Hiraoka M; Mizowaki T
Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):191-201. PubMed ID: 32768158
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial.
Li H; Fang Y; Gu D; Du M; Zhang Z; Sun L; Zhou G; Ye J
Radiat Oncol; 2022 Jun; 17(1):105. PubMed ID: 35681233
[TBL] [Abstract][Full Text] [Related]
19. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ
Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
